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Imaging of HER2 with [89Zr]pertuzumab in Response
to T-DM1 Therapy
Adriana V.F. Massicano,1 Supum Lee,2 Bryant K. Crenshaw,1 Tolulope A. Aweda,1 Retta El Sayed,1
Ian Super,1 Ron Bose,3 Bernadette V. Marquez-Nostra,2 and Suzanne E. Lapi1
Abstract
Background: The success of human epidermal growth factor receptor 2 (HER2)-targeted therapy depends on
accurate characterization of HER2 expression, but current methods available have several limitations. This
study aims to investigate the feasibility of [89Zr]pertuzumab imaging to monitor early response to Ado-
trastuzumab emtansine (T-DM1) therapy in mice bearing xenografts of HER2-positive breast cancer (BCa).
Materials and Methods: Pertuzumab was conjugated to DFO-Bz-NCS and labeled with 89Zr. Mice bearing BT-
474 tumors were imaged with [89Zr]pertuzumab and [18F]FDG before and after T-DM1 therapy.
Results: Pertuzumab was successfully labeled with 89Zr with a specific activity of 0.740 MBq/lg. Overall
[18F]FDG images showed poor delineation of tumors. Using [18F]FDG-PET to measure tumor volume, the
volume remained unchanged from 107.6 – 20.7 mm3 before treatment to 89.87 – 66.55 mm3 after treatment. In
contrast, [89Zr]pertuzumab images showed good delineation of HER2-positive tumors, allowing accurate de-
tection of changes in tumor volume (from 243.80 – 40.91 mm3 before treatment to 78.4 – 40.43 mm3 after
treatment).
Conclusion: [89Zr]pertuzumab may be an imaging probe for monitoring the response of HER2-positive BCa
patients to T-DM1 therapy.
Keywords: [89Zr]pertuzumab, HER2-positive breast cancer, T-DM1 therapy, molecular imaging, radiolabeled
monoclonal antibody
Introduction
The human epidermal growth factor receptor 2 (HER2)has been extensively studied for several years because of
its importance and prevalence in cancer cells. Some cancers,
including bladder, lung, gastric, ovarian, prostate, and breast
cancer (BCa) may present amplification of the HER2 gene
that often leads to the overexpression of the HER2 protein
on the cell surface.1 About 15%–20% of all BCa exhibit
HER2 overexpression/amplification and these tumor sub-
types are frequently more aggressive with poor prognosis.2,3
Fortunately, patients with HER2-positive BCa are eligible for
HER2-targeted therapy using monoclonal antibodies (mAbs).
The first anti-HER2 mAb approved by Food and Drug
Administration (FDA) was trastuzumab (Herceptin; Genen-
tech, South San Francisco, CA), which binds to the domain
IV of HER2, and its use has significantly improved patient
survival.3,4 Several other drugs and mAbs have been
developed for use as single agents or in combination with
trastuzumab. Pertuzumab (Perjeta; Genentech), is a
humanized mAb that binds to domain II of the extracel-
lular portion of HER2 inhibiting HER2 heterodimeriza-
tion with other HER family members.5 It is approved by
FDA for use in combination with trastuzumab and doce-
taxel as a first line therapy for metastatic HER2-positive
BCa.6
Ado-trastuzumab emtansine (T-DM1, Kadcyla; Genen-
tech) is a HER2-targeted antibody-drug containing DM1, a
derivative of maytansine conjugated to trastuzumab via a
stable thioether linker.7 T-DM1 retains all of trastuzumab’s
mechanisms of action and adds to it a potent inhibitor of
microtubule polymerization (DM1).8 Clinically, T-DM1 has
1Department of Radiology, The University of Alabama at Birmingham, Birmingham, Alabama.
2Department of Radiology and Biomedical Imaging, PET Center, Yale University, New Haven, Connecticut.
3Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri.
Address correspondence to: Suzanne E. Lapi; Department of Radiology, The University of Alabama at Birmingham; 1824 6th Avenue
South, WTI 310F, Birmingham, AL 35294
E-mail: lapi@uab.edu
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
Volume 34, Number 4, 2019

















































been well tolerated by patients with minimal adverse effects
and has increased patient survival.9,10
Since the success of this type of therapy depends directly
on the level of HER2 present on the cell surface, determi-
nation of HER2 expression is very important. Currently,
there are two types of tests available to measure HER2
status in biopsies: (1) immunohistochemistry (IHC) that
detects HER2 overexpression, and (2) fluorescence in situ
hybridization (FISH) that detects HER2 gene amplifica-
tion.11 There is evidence that HER2 expression changes
during the course of disease and therapy12 and for that
reason, many protocols encourage repeated biopsies through-
out the treatment.13 However, it has been reported that up to
20% of results using these methods may be inaccurate.11
Furthermore, since these methods use small sample of biop-
sied tumors and due to the intra-tumor heterogeneity, these
methods may not represent the status of HER2 expression
in the whole tumor and/or in the metastatic foci.1,14
To develop more specific agents to detect HER2 ex-
pression, several groups have labeled mAbs with different
radioisotopes for single-photon emission computed tomog-
raphy (SPECT) and positron emission tomography (PET)
imaging. These radiopharmaceuticals used for molecular
imaging exhibit an immense advantage because they are
HER2-targeted and therefore, are more specific than other
imaging techniques. Advantages of targeting HER2 in nu-
clear medicine are discussed in a recent review.15 Trastu-
zumab is the most studied HER2 mAb and in several
previous studies, labeled trastuzumab has shown promise as
an option to assess HER2 status in patients with HER2-
positive BCa.12,16–21
In addition to this approach, [89Zr]trastuzumab was used
in a recent study to identify patients unlikely to benefit from
T-DM1 therapy, illustrating the potential utility of HER2
imaging to improve T-DM1 patient selection.22
Nevertheless, during trastuzumab and/or T-DM1 therapy,
imaging with radiolabeled trastuzumab may be problematic
due to the saturation of epitope IV of HER2 receptors.
Several studies show pertuzumab does not compete with
trastuzumab in vitro and in vivo,23–25 since they bind to a
different epitope of HER2.5 Interestingly, one recent study
illustrated the presence of trastuzumab enhanced radio-
labeled pertuzumab uptake in HER2-positive tumors.23
Therefore, using imaging agents based on pertuzumab while
treating with trastuzumab or T-DM1 may allow a more
sensitive detection of HER2 without binding competition.23
This study aimed to evaluate the utility of [89Zr]pertuzumab




The production of 89Zr-oxalate was carried out in house
(University of Alabama at Birmingham, Cyclotron Facility)
using 89Y sputtered solid targets as described previously.26
Pertuzumab (Perjeta) and Ado-trastuzumab emtasine (Kadcyla)
were purchased from Genentech. Anti-HER2 (Neu C-18;
sc-284), anti-b actin (sc-47778 HRP), and goat antirabbit
IgG-HRP (sc-2054) antibodies for western blotting were
purchased from Santa Cruz Biotechnology (Dallas, TX).
Desferrioxamine-p-benzyl-isothiocyanate (DFO-Bz-NCS) was
purchased from Macrocyclics (Dallas, TX). Dimethyl sulf-
oxide (DMSO) and sodium carbonate were purchased from
Sigma-Aldrich (St. Louis, MO). HEPES was purchased
from ACROS Organic (Fair Lawn, NJ). All other chemicals
were purchased from Fisher Scientific (Hampton, NH) un-
less stated otherwise.
Cell culture
The BT-474 (HER2-positive) cell line was purchased
from American Type Culture Collection (ATCC) and cul-
tivated in Dulbecco’s Modified Eagle Medium (DMEM)
containing 10% fetal bovine serum (FBS) and 10 mg/mL
gentamycin in a humidified incubator with 5% CO2 at 37C.
BT-474 cells were supplemented with 0.01 mg/mL of hu-
man insulin (Sigma-Aldrich, St. Louis, MO). JIMT-1
(HER2-positive) cell was purchased from AddexBio (San
Diego, CA) and cultivated in Iscove’s Modified Dulbecco’s
Medium (IMDM) with 10% FBS and gentamycin (10 mg/ML)
at the same conditions cited above. All other reagents for
cell culture were purchased from Gibco Life Technologies
(Grand Island, NY).
Preparation of [89Zr]pertuzumab
Conjugation of DFO-Bz-NCS to pertuzumab and radio-
labeling with 89Zr-oxalate were performed following pre-
vious methods.23,27 Briefly, 8, 10, 16, and 20-fold molar
excess of DFO-Bz-NCS dissolved in DMSO were incubated
with pertuzumab in 0.1 M sodium carbonate buffer (pH 9) at
37C for 1 h. After the conjugation, the DFO-pertuzumab
conjugate was purified and buffer exchanged into 1 M
HEPES buffer pH 7.1–7.3 via Zeba spin desalting columns
(40 kDa Molecular Weight Cut-Off; Thermo Scientific,
Rockford, IL). The final concentration of protein was quan-
tified using a bicinchoninic acid (BCA) assay (Thermo Sci-
entific, Rockford, IL). The purified DFO-pertuzumab was
labeled with neutralized 89Zr-oxalate using an activity of 0.148,
0.296, 0.370, and 0.710 MBq per lg mAb in a final volume
of 100 lL at 37C for 1 h.
The radiochemical yield (RCY) was determined by in-
stant thin-layer chromatography (iTLC) using 50 mM DTPA
as the developing solution or by size exclusion high per-
formance liquid chromatography (SE-HPLC) using a size-
exclusion column (BioSep SECs-3000, 300 · 7.8 mm, 5 lm,
Phenomenex, CA) and 50 mM sodium phosphate, 150 mM
sodium chloride, 0.1%Tween-20 buffer as mobile phase, at a
flow rate of 1 mL/min. [89Zr]pertuzumab with RCYs ‡95%
chromatography was used for in vitro and in vivo studies
without further purification. When the yield was lower
than 95%, [89Zr]pertuzumab was purified using Zeba spin
desalting columns to achieve radiochemical purity (RCP)
‡95%.
Immunoreactivity
The immunoreactivity of conjugates was determined us-
ing the Lindmo28 assay in BT-474 cells. Briefly, cells were
harvested with trypsin and diluted in 1.5 mL microcentrifuge
tubes at a concentration ranging from 0.250 to 2.5 · 106 BT-
474 cells in phosphate buffered saline (PBS). An aliquot of
[89Zr]pertuzumab was diluted in 1% bovine serum albumin















































in PBS (1–2 lCi in 10 mL) and added to the BT-474 cells.
The cells were incubated for 1 h at room temperature with
gentle rocking. Afterward, the microcentrifuge tubes were
centrifuged and the pelleted cells obtained were washed
three times with cold PBS. The data were plotted as total
activity added to the cells/total activity bound to the cells
(Y axis) versus the cell concentration (mL/million) (X axis).
Afterward, the graph was fit by a linear regression using
Microsoft Excel 2010 software. The immunoreactivity was
calculated by (1/Y intercept) multiplied by 100.
Stability study in vitro
[89Zr]pertuzumab was diluted in NaCl 0.9% (0.1 MBq/lL),
incubated at either 4C – 2C or room temperature for 48 h.
At specific time points (1, 4, 24, and 48 h), aliquots of 1 lL
were spotted on ITLC plates and the RCY evaluated as de-
scribed previously. The stability was also evaluated in human
and mouse serum in vitro by SE-HPLC. [89Zr]pertuzumab
was diluted in human or mouse serum (Fisher Scientific, MA)
to a radioactivity concentration of 37 MBq/mL. A control
consisted of [89Zr]pertuzumab diluted in PBS. The samples
were incubated at 37C for 7 d. Aliquots of 30 lL were an-
alyzed in duplicate by SE-HPLC daily using protocol de-
scribed above. The radioactive peaks were analyzed using a
Sodium Iodide (NaI) detector (Lab Logic, FL) coupled with
an Agilent HPLC (model 1260 Infinity; Agilent, CA),
equipped with Laura software (version 4.5; Lab Logic).
Specific cell binding in vitro
The specific binding of [89Zr]pertuzumab was assessed in
BT-474 and JIMT-1 cells in vitro. Cells (1 · 106) were in-
cubated with [89Zr]pertuzumab (5 nM in IMDM or DMEM
1% FBS) alone (total binding) or in presence of cold per-
tuzumab (5 lM in IMDM or DMEM 1% FBS) (competitive
binding) for 1.5 h at room temperature with gentle rocking.
The cells were washed with PBS and assayed in a gamma
counter. The percentage of [89Zr]pertuzumab bound to the
cells in presence or absence of competitor was calculated.
Western blotting
BT-474 and JIMT-1 cells were lysed with RIPA buffer
(Alfa Aesar, MA) and the protein concentration in the ex-
tracted lysates was measured by BCA assay. Proteins
(20 lg) were loaded onto Any kD Mini-PROTEAN TG
precast gels (Biorad, Hercules, CA) in Tris/Glycin/SDS
buffer for electrophoresis. For western blotting, the pro-
teins in the gel separated by electrophoresis were transferred
onto PVDF membranes (Biorad). The membranes were
blocked with 3% nonfat dry milk (NFDM) in PBST for 1 h
at room temperature and incubated with anti-HER2 primary
antibody (C-18, 1 lg/mL in 3% NFDM) overnight at 4C.
The membranes were then washed and incubated with goat
antirabbit HRP-conjugated antibody (50 ng/mL in 3% NFDM)
and anti-b actin (100 ng/mL in 3% NFDM) for 1 h at room
temperature. After extensive washing, the membranes were
incubated with a chemiluminescent western blotting detec-
tion reagent (ECL Select; GE Healthcare, Chicago, IL) ac-
cording to manufacturer’s instructions and measured using a
ChemiDoc XRS+ imager (Biorad). The HER2 bands were
normalized by the amount of protein loaded (b-actin band)
using ImageJ software (National Institutes of Health, Be-
thesda, MD).
Animal studies
Tumor model. All animal experiments were performed
in accordance with guidelines of the Institutional Animal
Care and Use Committee (IACUC) at the University of
Alabama at Birmingham under an approved animal proto-
col. In vivo PET imaging studies were conducted in 5-week-
old athymic nu/nu female mice (Charles River Laboratories,
Wilmington, MA). A schema of in vivo tumor model and
therapy protocol used in this work is shown in Figure 1.
Mice were subcutaneously implanted with 60-d release
pellets containing 0.72 mg of 17b-estradiol (Innovative
Research of America, Sarasota, FL) on day -52. One week
after the pellet implantation (day -45), mice were subcuta-
neously inoculated on the left shoulder with 1 · 107 cells/mL
of BT-474 cells suspended in 100 lL PBS. Tumors were
allowed to grow for 5 weeks.
Evaluation of tumor size changes after T-DM1 treatment
in BT-474 HER2-positive xenografted mice. Mice were
divided into 2 groups of 4 mice (control and treatment). On
day -7 (Fig. 1), mice were injected via tail-vein with 7.4 MBq
(200 lCi) of 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG;
PETNET Solutions, Birmingham, AL) and static PET base-
line images were acquired for 20 min, 1 h postinjection (p.i)
using a Flex Triumph small animal PET/CT (TriFoil Imaging,
Chatsworth, CA). On day -6, the same mice were injected
via tail-vein with 3.7 MBq (100 lCi) of [89Zr]pertuzumab
(specific activity 592 MBq/mg) diluted in saline and static
PET baseline images were acquired as described above at
5 d p.i. On day 0 mice belonging to the treatment group
received 15 mg/kg of T-DM1 diluted in 100 lL of saline via
tail-vein while mice belonging to the control group received
100 lL of saline via tail-vein.
Two weeks after the T-DM1 administration, (on day +14)
the imaging protocols using [18F]FDG and [89Zr]pertuzu-
mab were repeated. The images were reconstructed using a
FIG. 1. In vivo tumor model development and therapy protocol schema.















































MLEM three-dimensional protocol and analyzed by Inveon
Research Workplace software (Siemens, Knoxville, TN).
The tumor volumes were calculated by region of interest
(ROI) drawn on the PET/CT images before and after T-DM1




Where r is the radioactivity concentration [kBq/mL] within
a ROI, a¢ is the decay-corrected amount of injected radio-
pharmaceutical [kBq], and w is the mouse weight [g].
The changes in tumor size were evaluated by caliper
weekly and by PET/CT imaging as described above.
HER2 quantification in tumors. The tumors were excised
following the final imaging session and flash frozen in liquid
nitrogen. Tissues were pulverized using a cell crusher and
FIG. 2. RCY of pertuzumab
conjugated to DFO at different molar
ratios and labeled with 89Zr at
4 lCi/lg (A); RCY of pertuzumab
conjugated to DFO at molar ratio 1:16
and labeled with 89Zr at different
ratios (B); Radiochromatogram
of [89Zr]pertuzumab (C). RCY,
radiochemical yield. Color images are
available online.















































proteins were extracted using RIPA buffer. HER2 quantifi-
cation was conducted using a Quantikine ELISA kit (R&D
Systems, MN) following supplier instructions. Concentra-
tions of HER2 were normalized to total protein using BCA
assay.
Statistical analysis
Statistical analysis was performed using Student’s t-test
( p < 0.05) for single comparison and one-way or two-way
analysis of variance for multiple comparison followed
by Bonferroni post-test. All analyses were performed on
GraphPad Prism V5 (GraphPad Software, Inc., La Jolla,
CA).
Results
Preparation and characterization of [89Zr]pertuzumab
Pertuzumab was conjugated to DFO-Bz-NCS by com-
bining 8, 10, 16, or 20 moles of chelator to 1 mole of mAb at
pH 9 for 1 h at 37C, followed by prompt purification. The
conjugated antibody was labeled with 89Zr (0.148 MBq/lg). The
RCY achieved for the molar ratio 1:8 were significantly
lower ( p < 0.05) compared with molar ratios 1:10 and 1:16.
For molar ratios 1:10 and 1:16 the RCY were higher than
90% without any further purification. When a purification
step was added, all molar ratios presented RCP greater than
92%; the molar ratios 1:16 and 1:20 showed RCP superior
to 95% (Fig. 2A).
The mAb conjugated at molar ratio 1:16 was labeled with
89Zr at different activity concentrations and showed RCY
greater than 95% for all conditions studied with no addi-
tional purification needed (Fig. 2B). This molar ratio al-
lowed a specific activity of 0.740 MBq/lg with minimum
formation of aggregates after labeling, as showed by SE-
HPLC (Fig. 2C).
Stability in NaCl 0.9% and human serum
The radiochemical stability of [89Zr]pertuzumab in 0.9%
NaCl was used to inform the expiration time of [89Zr]per-
tuzumab to plan further in vitro and in vivo experiments.
Four different lots of labeled antibody were evaluated by
iTLC up to 48 h at two different storage temperature (room
temperature and at 2C–8C). All lots presented RCP of
99.94% – 0.06% at the time of preparation. After 24 h, the
labeled antibody presented a RCP of 96.08% – 1.89% when
incubated at 2C–8C and 93.63% – 1.67%, n = 4, ( p = 0.368)
when incubated at room temperature (Fig. 3A). When the
RCP at 24 h was compared to the initial RCP, the incubation
at 4C – 2C showed no significant difference ( p = 0.088),
while the incubation at room temperature showed signifi-
cantly lower RCP ( p = 0.009), indicating this storage con-
dition is not ideal for this compound. After 48 h at room
temperature, the RCP decreased more than 10% from the
initial value (87.77% – 3.20%) while storage at 2C–8C
resulted in better preservation of the RCP after 48 h of in-
cubation (91.98% – 3.56%).
[89Zr]pertuzumab was incubated in PBS, human and
mouse serum at 37C up to 7 d and stability was evaluated
by SE-HPLC (Fig. 3B). For all three conditions, the RCP
corresponds to [89Zr]pertuzumab monomer, which decreased
by 12% in 24 h.
For incubation in mouse and human serum, it was ob-
served that the RCP decrease was mostly due to the for-
mation of aggregates or transchelation of 89Zr to serum
proteins. However, after day 5, free 89Zr was observed in the
chromatograms for both conditions. For [89Zr]pertuzumab
incubated in PBS the main impurity observed was free 89Zr
with minimal formation of aggregates.
Cell binding studies in vitro and western blotting
HER2-positive BT-474 cells were used to determine
[89Zr]pertuzumab immunoreactivity by Lindmo assay. The
immunoreactivity fraction was calculated to be 79.4% – 6.1%;
74% – 11.8%; 75.1% – 1.0%; and 67.2% – 2.4% for molar
ratios 1:8, 1:10, 1:16, and 1:20 respectively. At molar ratio
1:20, the immunoreactivity decreased more than 10% com-
pared to the labeling at a molar ratio 1:8, however, this
difference was not significant ( p = 0.1191).
The specificity of [89Zr]pertuzumab binding to HER2
cells was investigated in BT-474 and JIMT-1 cells (Fig. 4A).
Significantly higher binding was observed in BT-474
(36.46% – 0.05% of total radioactivity added) compared to
JIMT-1 (7.30% – 0.02% of total radioactivity added) ( p < 0.01).
For both cells, competitive binding studies showed de-
creased uptake of [89Zr]pertuzumab in the presence of non-
labeled antibody (0.18% – 0.09% and 0.24% – 0.05% of total
radioactivity added for BT-474 and JIMT-1 cells respec-
tively), demonstrating that the uptake of [89Zr]pertuzumab
was HER2-specific.
FIG. 3. Stability of [89Zr]pertuzumab in NaCl 0.9% at
room temperature and 4C (A). Stability of [89Zr]pertuzu-
mab in human serum, mouse serum, and PBS at 37C
(B). PBS, phosphate buffered saline.















































HER2 expression in BT-474 and JIMT-1 was evaluated
by western blotting assay. A strong band with molecular
weight of 185 kDA, corresponding to HER2 protein, was
observed in both cell lines; however, the band in BT-474
cells was stronger than JIMT-1 (Fig. 4B). After normaliza-
tion to total protein loaded (b-actin band), the HER2:b-actin
ratio was significantly higher for BT-474 cells than for
JIMT-1 cells ( p = 0.0141; Fig. 4C) and this result corrobo-
rates with the cell binding assay results. Due to the higher
HER2 expression found in BT-474 cells, this cell line was
used for all following experiments.
Development of mice tumor model
Estrogen pellets are commonly used to stimulate tumor
growth of BT-474 cells in athymic nude mice. Using this
technique, we observed a tumor take rate of 100% after 5
weeks of cell implantation. However, the tumors were var-
ied in size (250.35 – 167.82 mm3). For this reason, mice
were divided in two groups of similar tumor sizes.
Evaluation of tumor size changes after T-DM1
treatment in BT-474 HER2-positive xenograft mice
Tumors measured by caliper 2 weeks post T-DM1 ther-
apy showed the treated tumors decreased by 48% in volume
whereas the tumor volume in the control group increased by
219% (Fig. 5A).
The variance in tumor size as a consequence of T-DM1
therapy was also evaluated by PET/CT imaging. Baseline
and post T-DM1 therapy images were acquired using
[18F]FDG and [89Zr]pertuzumab produced in the optimized
conditions (molar ratio DFO:mAb of 1:16; labeling condi-
tion of 0.740 MBq/lg).
The [18F]FDG images showed nonspecific uptake in heart
and brown fat with relatively little tumor uptake (Fig. 6A, C).
In contrast, [89Zr]pertuzumab images showed intense tumor
FIG. 4. Uptake of [89Zr]pertuzumab in BT-474 and JIMT-
1 cells (A). Western blot of BT-474 and JIMT-1. Anti-
HER2 antibody (C-18) was used to characterize the HER2
expression, and expression of b-actin was used as the
loading control (B). HER2:b-actin ratio for BT-474 and
JIMT-1 cells (C). HER2, human epidermal growth factor
receptor 2.
FIG. 5. Effect of T-DM1 therapy in HER2-positive BCa
BT-474 xenograft. Athymic nude mice bearing BT-474 tu-
mors were treated (4 mice per group) with saline (control
group) or T-DM1 (15 mg/kg, single administration, i.v.).
Tumor volume was measured weekly by caliper (A) and by
using ROI from PET/CT images before and after therapy
using [18F]FDG and [89Zr]pertuzumab as a radiopharma-
ceutical (B). BCa, breast cancer; CT, computed tomogra-
phy; PET, positron emission tomography; ROI, region of
interest; T-DM1, Ado-trastuzumab emtansine. Color images
are available online.















































uptake with only modest uptake in normal organs. Fur-
thermore, the images with [89Zr]pertuzumab showed good
tumor delineation that led to clear visualization of changes
in tumor size after T-DM1 therapy (Fig. 6B, D).
Attempts to delineate the tumor using only CT images
(Fig. 6 bottom row), were unsuccessful as after T-DM1
therapy the tumors became too small to identify via CT in
the treated group. Although CT is used clinically, it may not
be ideal to measure regression of tumors in patients with
high specificity. [89Zr]pertuzumab PET/CT images showed
significantly better tumor delineation than [18F]FDG (Fig. 5B).
[89Zr]pertuzumab PET/CT images allowed for detection of
changes in tumor volume in the T-DM1 group (from 243.8 –
40.91 mm3 to 78.40 – 40.43 mm3; p = 0.0282), which also
corresponded to caliper measurements, however, [18F]FDG
poorly detected tumor volume changes in the T-DM1
group (107.60 – 20.72 mm3 to 80.87 – 66.55 mm3; p = 0.7824)
(Fig. 5B).
The mean SUV for both imaging time points, showed that
[89Zr]pertuzumab had a significantly higher SUV before and
after therapy when compared with [18F]FDG ( p < 0.0001;
Table 1). However, there were no significant changes in the
SUV before and after therapy for both radiopharmaceuticals
( p > 0.05).
HER2 quantification in the tumors indicated there was
no difference ( p = 0.1196) between HER2 concentration in
the control group (0.213 – 0.217 pg/mL of HER2 per tumor)
and the group treated with T-DM1 (0.016 – 0.009 pg/mL of
HER2 per tumor). This result is in agreement with the lack of
change in [89Zr]pertuzumab tumor uptake before and after
treatment. Thus, T-DM1 treatment did not impact HER2 ex-
pression in our model.
Discussion
HER2-positive BCa represents approximately 20% of all
BCa and HER2 expression is associated with poor prognosis
and more aggressive cancer subtypes 3. Patients who have
HER2-positive cancers can benefit from targeted therapy
using targeted mAbs. As the success of this therapy relies
directly on levels of HER2 present in the tumor, an accu-
rate quantification of HER2 expression is crucial. In this
scenario, molecular imaging can provide a better tool for
patient stratification, and monitoring during the course of
therapy.
In this article we describe the use of [89Zr]pertuzumab as
a radiopharmaceutical for monitoring response to T-DM1
therapy in mice bearing BT-474 tumors. Our data demon-
strate high tumor uptake of [89Zr]pertuzumab in HER2-
positive BCa tumors with minimal nonspecific on nontarget
organs. Also, our data confirm that [18F]FDG is not suit-
able for monitoring pharmacological response of the tumor
to T-DM1 in this model. This result is in agreement with
Janjigian et al. that showed [89Zr]trastuzumab was more
specific for imaging of HER2-positive gastric cancer than
[18F]FDG.20
Pertuzumab was successfully conjugated to DFO using a
molar ratio 1:16 that resulted in acceptable conservation of
immunoreactivity (75.1% – 1.0%). In addition, by using this
molar ratio conditions, we achieved a specific activity of
740 MBq/mg with RCY greater than 95% with no additional
purification or formation of aggregates after the labeling, as
shown by SE-HPLC.
The RCP of [89Zr]pertuzumab decreased by less than
4% (from 99.94% – 0.06% to 96.08% – 1.89%) when it was
stored in 0.9% NaCl for 24 h at 2C–8C indicating the
expiration time can be set for 24 h after labeling when stored
under this condition. The labeled antibody showed less
stability in human serum than in mouse serum (Fig. 3B).
The main impurity formed during the incubation in mouse
and human serum was aggregates or transchelation of 89Zr
to serum proteins, which might be explained by enzymatic
degradation of the antibody in presence of serum.
Our data showed that measurement of the tumor vol-
ume was similar with caliper or [89Zr]pertuzumab PET-CT
images (Fig. 5A, B) and both methods could detect the
significant tumor volume changes after T-DM1 therapy.
However, the tumor volume remained unchanged as as-
sessed by [18F]FDG PET/CT. [18F]FDG images showed
nonspecific uptake in heart and brown fat with relatively
FIG. 6. Posterior half body PET/CT images of Nu/Nu
mice implanted with BT-474 human BCa xenografts (white
arrows). Baseline imaging acquired before therapy with T-
DM1 using [18F]FDG (A) and [89Zr]pertuzumab (B) and
after therapy using [18F]FDG (C) and [89Zr]pertuzumab
(D). Color images are available online.
Table 1. Standard Uptake Value Mean
Calculated Before (Baseline Imaging)

















[18F]FDG—control group 3.8 – 0.9 4.7 – 3.1
[89Zr]pertuzumab—control group 40.6 – 7.5 43.2 – 8.3
[18F]FDG—T-DM1 group 4.0 – 1.9 3.5 – 3.4
[89Zr]pertuzumab—T-DM1 group 41.9 – 2.0 47.5 – 15.9
SUV, standard uptake value; T-DM1, Ado-trastuzumab emtan-
sine.















































little tumor uptake. In contrast, [89Zr]pertuzumab images
showed more specificity in vivo with good tumor delinea-
tion, which led to clear visualization of changes in tumors
size after T-DM1 therapy.
No significant changes in the SUV values were observed
before and after therapy for both radiopharmaceuticals
( p > 0.05). This result suggests that even though the therapy
was effective, as evidenced by tumor size regression, it did
not affect tumor metabolism and/or HER2 expression.
Computed tomography is often used to investigate tumor
mass in patients. Although it is possible to detect the tumor
volume changes in our model using only CT images (Fig. 6),
the tumor margins were not clearly visible. This character-
istic hampered accurate assessment of tumor volumes
changes via CT especially among the treated group.
Another important finding from this study is that T-DM1
did not downregulate HER2 expression and even though the
tumor decreased in size, HER2 concentration was similar in
both groups as measured by ELISA. In this particular model,
continuing the therapy with T-DM1 or another HER2-
targeted therapy would be possible.
Although promising, our study has limitations. First, the
sample size of each group was small. Therefore, any find-
ings from this study may be limited by the small sample
size. However, it is known that the BT-474 animal model is
sensitive to T-DM1, so the response to the treatment was
expected.29–31 Second, we used a cell line with high ex-
pression of HER2. Further studies using another cell line
with different HER2 expression are warranted to evaluate
whether [89Zr]pertuzumab would be able to identify changes
in the tumor volume in models with variable HER2 ex-
pression.
Our study shows [89Zr]pertuzumab can be used to mon-
itor the efficacy of T-DM1 therapy even after a single
therapeutic dose and may aid in determining whether
treatment is effective in patients undergoing T-DM1 or
trastuzumab therapy to help guide physicians toward tai-
lored treatment for each patient. This hypothesis is re-
inforced by a recent study published by Ulaner et al. This
first-in-human study evaluated the dosimetry and tis-
sues biodistribution of [89Zr]pertuzumab in patients with
metastatic BCa HER2-positive. Even though, all 6 patients
enrolled had metastasis previously treated with systemic
therapy and HER2-targeted therapy, the authors conclude
that these therapies did not interfere in the HER2-targeted
imaging with [89Zr]pertuzumab.32
Other potential applications of [89Zr]pertuzumab are the
selection of patients for therapy with trastuzumab and
T-DM1 based on their HER2 expression levels and the
assessment of HER2 heterogeneity. In these settings,
[89Zr]pertuzumab might have an advantage over the meth-
ods currently used to measure HER2 status using biopsies
(IHC and FISH).
Conclusions
[89Zr]pertuzumab showed high uptake in HER2-positive
tumor with high selectivity that led to clear visualization of
changes in tumor size after T-DM1 therapy. This radio-
pharmaceutical showed potential for noninvasive detection
of initial response of HER2-positive BCa undergoing T-
DM1 therapy in vivo.
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